lopinavir/ritonavir - for COVID-19 method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.04 [0.59, 1.82]> 162%2 studies (2 / -)55.6 %some concernnot evaluable moderatecrucial-
clinical improvement (28-day) 1.59 [0.84, 3.03]> 10%1 study (1 / -)92.1 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 1.31 [0.94, 1.83]> 10%1 study (1 / -)94.4 %some concernnot evaluable moderatecrucial-
clinical worsening 3.69 [0.37, 36.57]< 10%1 study (1 / -)13.4 %some concernnot evaluable moderatecrucial-
deaths 1.00 [0.80, 1.25]< 114%2 studies (2 / -)49.7 %some concernnot evaluable moderatecrucial-
PCR-negative conversion 1.28 [0.19, 8.76]> 10%1 study (1 / -)59.9 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 0.92 [0.80, 1.06]> 10%2 studies (2 / -)12.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 0.73 [0.37, 1.43]> 12%2 studies (2 / -)18.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only)no RCT reported results for this endpoint, but 1 observational studies are available. Clear RCT filter to include observational studies
radiologic improvement (14-day) 0.75 [0.53, 1.06]> 10%2 studies (2 / -)4.9 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.10 [0.00, 2.09]> 10%1 study (1 / -)7.2 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 91, 95, 87